You're missing the point, Skippy. Whatever the official reason for running REDUCE-IT, anyone with even a shred of insight into where this drug was heading would’ve known to include a statin-intolerant arm. Failing to do so wasn’t just an oversight — it was flat-out incompetence. No excuse covers a blunder that obvious.
Market Data 
Markets 
AI
